Asad Haider, head of the U.S. Healthcare Business Unit at Goldman Sachs Research, says 2026 is a pivotal year for the obesity market due to upcoming oral drug launches. He tells Romaine Bostick and Katie Greifeld on “The Close” that investor psychology around the sector this year will be closely tied to how those launches perform. (Source: Bloomberg)
www.bloomberg.com
#Goldman039s #Haider #Pivotal #Year #Obesity #Market #Pharma
Goldman's Haider: Pivotal Year for Obesity Market in Pharma
